Aldeyra Therapeutics Inc. (NASDAQ: ALDX)
$3.97
+0.1050 ( +2.72% ) 218.7K
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
Market Data
Open
$3.97
Previous close
$3.86
Volume
218.7K
Market cap
$235.28M
Day range
$3.75 - $3.97
52 week range
$1.42 - $8.38
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Mar 12, 2024 |
10-k | Annual reports | 89 | Mar 07, 2024 |
8-k | 8K-related | 34 | Feb 13, 2024 |
8-k | 8K-related | 13 | Jan 04, 2024 |
8-k | 8K-related | 12 | Dec 21, 2023 |
8-k | 8K-related | 33 | Dec 19, 2023 |
8-k | 8K-related | 22 | Nov 28, 2023 |
10-q | Quarterly Reports | 69 | Nov 03, 2023 |
8-k | 8K-related | 12 | Nov 01, 2023 |
4 | Insider transactions | 1 | Oct 18, 2023 |